Prometheus Biosciences to Participate at the Cowen 42nd Annual Healthcare Conference

Rhea-AI Summary

On March 1, 2022, Prometheus Biosciences (Nasdaq: RXDX) announced that CEO Mark McKenna and management will participate in a virtual fireside chat at the Cowen 42nd Annual Healthcare Conference on March 7, 2022, at 12:50 PM ET. The company focuses on precision medicine for immune-mediated diseases, utilizing its Prometheus360™ platform. Its lead candidate, PRA023, targets conditions like ulcerative colitis and Crohn’s disease, with ongoing Phase 2 trials. A live and archived webcast of the chat will be available on their Investor section web page.

SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that Mark McKenna, Chairman and CEO along with members of management, will conduct a virtual fireside chat at the Cowen 42^nd Annual Healthcare Conference on March 7, 2022 at 12:50 PM ET.

A live and archived webcast of the virtual fireside chat will be available via the Events & Webcasts page on the Investor section of the Prometheus Biosciences website.

About Prometheus Biosciences

Prometheus Biosciences, Inc. is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. The Company’s precision medicine platform, Prometheus360^TM, combines proprietary machine learning-based analytical approaches with one of the world’s largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets.

The Company’s lead candidate, PRA023, is an IgG1 humanized monoclonal antibody (mAb) for the treatment of immune-mediated diseases including Ulcerative colitis (UC), Crohn’s disease (CD), and the newly identified systemic sclerosis-associated interstitial lung disease (SSc-ILD). The Company is currently conducting a Phase 2 trial in UC patients and a Phase 2a trial in CD patients, each utilizing a proprietary genetic-based companion diagnostic designed to identify patients who are predisposed to increased expression of TL1A and therefore potentially more likely to respond to PRA023. The company also plans to initiate a Phase 2 clinical trial for PRA023 in SSc-ILD in the first quarter of 2022.

Prometheus Biosciences Contact:
Noel Kurdi
VP Investor Relations and Communications
(646) 241-4400
nkurdi@prometheusbiosciences.com

Media contact:
Juniper Point
Amy Conrad
(858) 914-1962
media@prometheusbiosciences.com

FAQ

What is the date and time of Prometheus Biosciences' virtual fireside chat?

Prometheus Biosciences' virtual fireside chat is scheduled for March 7, 2022, at 12:50 PM ET.

Where can I find the webcast of the Prometheus Biosciences fireside chat?

The webcast will be available on the Events & Webcasts page in the Investor section of the Prometheus Biosciences website.

What is the focus of Prometheus Biosciences as a biotechnology company?

Prometheus Biosciences focuses on precision medicine for discovering, developing, and commercializing treatments for immune-mediated diseases.

What is the lead candidate of Prometheus Biosciences?

The lead candidate of Prometheus Biosciences is PRA023, an IgG1 humanized monoclonal antibody targeting conditions like ulcerative colitis and Crohn’s disease.

What ongoing clinical trials is Prometheus Biosciences conducting?

Prometheus Biosciences is conducting Phase 2 trials for PRA023 in ulcerative colitis and Crohn’s disease patients, and plans to initiate a Phase 2 trial for systemic sclerosis-associated interstitial lung disease.